Discovery and recognition of purine receptor subtypes on platelets

✍ Scribed by Susanna M.O. Hourani

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 112 KB
• Volume: 52
• Category: Article
• ISSN: 0272-4391
• DOI: 10.1002/ddr.1108

✦ Synopsis

Abstract

The effects of purines on platelets have been known since the 1960s, when Born demonstrated aggregation induced by ADP and its inhibition by adenosine and by ATP. The inhibition by adenosine is not specific for ADP, and adenosine acts at a separate receptor to stimulate adenylate cyclase, which has an inhibitory effect on platelet function. Studies using selective agonists and antagonists have shown that the platelet receptor is of the A~2A~ subtype and this has been confirmed using A~2A~ knockout mice. The situation with ADP is more complex, and there has been controversy about the number of ADP receptors on platelets. ADP causes shape change, aggregation, mobilisation of calcium from intracellular stores, rapid calcium influx, and inhibition of adenylate cyclase, and the relationship between these is becoming clearer. Two cloned P2 receptors have been detected on platelets, P2X~1~ and P2Y~1~, and a third P2Y receptor is thought to exist. The P2X~1~ receptor is responsible for the rapid calcium influx and can be activated by ATP as well as by ADP, but is likely to be desensitised under normal experimental conditions and its pathophysiological role is uncertain. The P2Y~1~ receptor is responsible for calcium mobilisation, shape change, and the initiation of aggregation, and these responses are abolished in P2Y~1~ knockout mice, while the other P2Y receptor is responsible for inhibition of adenylate cyclase and is required for full aggregation. ATP is a competitive antagonist at both these P2Y receptors, while some nucleotide analogues can discriminate between them. Drug Dev. Res. 52:140–149, 2001. © 2001 Wiley‐Liss, Inc.